FDA declines to approve Capricor’s deramiocel for the treatment of Duchenne

Despite recognition of the tremendous unmet medical need in Duchenne muscular dystrophy, the FDA has decided that the evidence is not sufficient to approve Capricor’s deramiocel for the treatment of Duchenne and issued a Complete Response Letter to the company this afternoon. This decision has come after a review of the original application, a public advisory committee meeting, and consideration of a major amendment–with additional data that included 24-month open-label extension findings from the HOPE-3 study recently submitted by Capricor.
This news is deeply disappointing to the Duchenne community, especially for those individuals and families who participated in the HOPE-2 and HOPE-3 clinical trials. Going forward, CureDuchenne will work with the company to explore possible next steps for deramiocel and will share updates with the community accordingly.
Capricor will hold a conference call and webcast on Monday 23rd at 8:30 am ET, with a recording also available afterwards.
For further information, see https://www.capricor.com/investors/news-events/press-releases/detail/360/capricor-therapeutics-provides-regulatory-update-on
FDA Link:




